Zoetis Inc. (ZTS)
Stock Price Chart
Key Info
| Market Cap | 76.58B |
| Revenue (ttm) | 6.34B |
| Net Income (ttm) | 1.62B |
| Shares Out | 475.15M |
| EPS (ttm) | 3.37 |
| PE Ratio | 47.83 |
| Forward PE | 39.37 |
| Dividend | $0.80 |
| Dividend Yield | 0.50% |
Stock Quote
| Trading Day | Oct 21, 2020 |
| Last Price | $161.18 |
| Previous Close | $159.49 |
| Change ($) | 1.69 |
| Change (%) | 1.06% |
| Day's Open | 159.50 |
| Day's Range | 159.50 - 162.13 |
| Day's Volume | 1,456,729 |
| 52-Week Range | 90.14 - 168.96 |
More Stats
| Market Cap | 76.58B |
| Enterprise Value | 81.08B |
| Earnings Date (est) | Nov 5, 2020 |
| Ex-Dividend Date | Oct 20, 2020 |
| Shares Outstanding | 475.15M |
| Float | 474.68M |
| EPS (basic) | 3.40 |
| EPS (diluted) | 3.37 |
| FCF / Share | 3.06 |
| Dividend | $0.80 |
| Dividend Yield | 0.50% |
| Earnings Yield | 2.09% |
| FCF Yield | 1.90% |
| Payout Ratio | 21.40% |
| Shares Short | 3.82M |
| Short Ratio | 2.49 |
| Short % of Float | 0.80% |
| Beta | 0.70 |
| PE Ratio | 47.83 |
| Forward PE | 39.37 |
| P/FCF Ratio | 52.60 |
| PS Ratio | 12.08 |
| PB Ratio | 25.97 |
| Revenue | 6.34B |
| Operating Income | 2.17B |
| Net Income | 1.62B |
| Free Cash Flow | 1.46B |
| Net Cash | -4.50B |
| Net Cash / Share | -9.46 |
| Gross Margin | 68.91% |
| Operating Margin | 34.18% |
| Profit Margin | 25.50% |
| FCF Margin | 22.97% |
| ROA | 11.78% |
| ROE | 59.87% |
| ROIC | 20.70% |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6,260 | 5,825 | 5,307 | 4,888 | 4,765 | 4,785 | 4,561 | 4,336 | 4,233 | 3,582 |
| Revenue Growth | 7.47% | 9.76% | 8.57% | 2.58% | -0.42% | 4.91% | 5.19% | 2.43% | 18.17% | - |
| Gross Profit | 4,268 | 3,914 | 3,532 | 3,222 | 3,027 | 3,068 | 2,892 | 2,773 | 2,581 | 2,138 |
| Operating Income | 2,024 | 1,896 | 1,700 | 1,394 | 669 | 937 | 803 | 741 | 430 | 178 |
| Net Income | 1,500 | 1,428 | 864 | 821 | 339 | 583 | 504 | 436 | 245 | 110 |
| Shares Outstanding | 478 | 483 | 490 | 496 | 500 | 501 | 500 | 500 | 500 | 500 |
| Earnings Per Share | 3.11 | 2.93 | 1.75 | 1.65 | 0.68 | 1.16 | 1.01 | 0.87 | 0.49 | 0.22 |
| EPS Growth | 6.14% | 67.43% | 6.06% | 142.65% | -41.38% | 14.85% | 16.09% | 77.55% | 122.73% | - |
| Dividend Per Share | 0.66 | 0.50 | 0.42 | 0.38 | 0.33 | 0.29 | 0.20 | - | - | - |
| Dividend Growth | 30.16% | 20% | 10.53% | 14.46% | 15.28% | 47.69% | - | - | - | - |
| Operating Cash Flow | 1,795 | 1,790 | 1,346 | 713 | 664 | 626 | 681 | 454 | 497 | 254 |
| Capital Expenditures | -460 | -338 | -224 | -216 | -224 | -180 | -184 | -126 | -135 | -124 |
| Free Cash Flow | 1,335 | 1,452 | 1,122 | 497 | 440 | 446 | 497 | 328 | 362 | 130 |
| Cash & Equivalents | 1,934 | 1,701 | 1,564 | 727 | 1,154 | 882 | 610 | 317 | 79.00 | 63.00 |
| Total Debt | 6,611 | 6,452 | 4,953 | 4,468 | 4,868 | 3,631 | 3,657 | 582 | 575 | 711 |
| Net Cash / Debt | -4,677 | -4,751 | -3,389 | -3,741 | -3,714 | -2,749 | -3,047 | -265 | -496 | -648 |
| Assets | 11,545 | 10,777 | 8,586 | 7,649 | 7,913 | 6,588 | 6,558 | 6,262 | 5,711 | 5,284 |
| Liabilities | 8,837 | 8,592 | 6,800 | 6,150 | 6,822 | 5,251 | 5,596 | 2,221 | 1,975 | 1,940 |
| Book Value | 2,708 | 2,185 | 1,770 | 1,487 | 1,068 | 1,311 | 940 | 4,026 | 3,720 | 3,344 |
Company Profile
Company Details
| Full Name | Zoetis Inc. |
| Country | United States |
| Employees | 10,600 |
| CEO | Kristin C. Peck |
Stock Information
| Ticker Symbol | ZTS |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | NYSE: ZTS |
| IPO Date | February 1, 2013 |
Description
Zoetis discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.